巴西官员：将把中国新冠疫苗纳入国家免疫计划

当地时间20日，巴西多位州长在与该国卫生部长会晤后宣布，除了制药巨头阿斯利康公司和英国牛津大学研制的疫苗外，巴西政府还将把中国科兴生物技术公司开发的新冠病毒疫苗CoronaVac纳入国家免疫计划。

圣保罗州州长若昂·多利亚表示，巴西联邦政府已经同意购买4600万剂中国制造的新冠病毒疫苗。他还称，巴西免疫接种计划最早将于2021年1月启动。

巴西圣保罗州布坦坦研究所19日表示，对9000名志愿者进行临床试验的初步结果证明，中国的疫苗是安全的，有关疫苗有效性的数据要等试验完成后才能公布。

The Brazilian government will include China's Sinovac vaccine against COVID-19 in its national immunization program, state governors said on Tuesday after a meeting with the country's health minister, in addition to one developed by AstraZeneca and Oxford University.

This means the experimental Chinese vaccine called Coronavac, which Brazil's largest state of Sao Paulo had hoped to provide to its residents, may also be used to vaccinate Brazilians elsewhere, a major success for Sinovac in a nation of 230 million people.

The federal government already has plans to purchase the UK vaccine and produce it at its biomedical research center FioCruz in Rio de Janeiro, while the Chinese vaccine is being tested by Sao Paulo state's research center Butantan Institute.

Sao Paulo Governor Joao Doria said after the Health Ministry meeting that the federal government has agreed to buy 46 million doses of the Sinovac vaccine.

The national vaccination program could begin in January 2021, he said, which could make it one of the first immunization efforts against coronavirus in the world.

The Butantan Institute said on Monday that preliminary results from late-stage clinical trials of CoronaVac on 9,000 volunteers have proven that the two-dose Chinese vaccine is safe.

Butantan director Dimas Covas said data on how effective the vaccine is will not be released until the trial is completed.

The result is only preliminary and researchers will keep monitoring the participants in the ongoing trial, Covas said. It's the first set of results of Sinovac's global Phase III trials, which are also being conducted in Turkey and Indonesia.

The Sao Paulo government has already asked health regulators to approve CoronaVac for use, a major step in what could be one of the first vaccination programs in the Americas.

Vaccine for all

在20日国务院联防联控机制召开的新闻发布会上，科技部社会发展科技司副司长田保国介绍，目前我国新冠疫苗研发工作总体处于领先地位，已有13个疫苗进入临床阶段。其中，灭活疫苗和腺病毒载体疫苗两种技术路线共4个疫苗进入三期临床，总体进展顺利。截至目前，共计约6万名受试者接种，未接到严重不良反应报告。

上周，50多位非洲国家驻华使节和高级外交官集体赴国药集团北京生物制品研究所参观，听取国药集团关于中国疫苗技术、新冠肺炎疫苗研发等情况介绍。

国家卫生健康委科技发展中心主任郑忠伟此前介绍，预计今年年底我国疫苗的产能能达到6.1亿剂。明年，我国新冠疫苗的年产能在此基础上会有效扩大，切实保证我国以及全球其他国家对中国新冠疫苗的需求。

At a Tuesday press conference, a Chinese official said nearly 60,000 people have been injected with China's COVID-19 vaccines so far and no one has reported severe adverse reactions.

Among the country's 13 vaccines in clinical trials, four candidates have entered Phase III trials with volunteers across 10 countries. In addition to Brazil, developing countries in Southeast Asia, and Africa have also undergone various Chinese vaccine experiments.

Last week, a group of ambassadors and diplomats from 50 African countries were invited to visit China's largest vaccine maker Sinopharm. In the vaccine factory, they were briefed about the Phase III clinical trials of the company's COVID-19 vaccine, which is being carried out in 10 countries including the United Arab Emirates, Peru and Argentina with more than 50,000 volunteers involved.

The company is the first to build a high-grade bio-safety production facility for the inactivated COVID-19 vaccine. It is estimated that the production capacity of the inactivated COVID-19 vaccine will reach more than 1 billion doses in 2021.

China, at large, is expected to produce up to 610 million doses of COVID-19 vaccines by the end of this year, Zheng Zhongwei, head of China's coronavirus vaccine development task force, said at an earlier press briefing, adding that the capacity will be further expanded next year to meet the huge demand.

推荐阅读：